CN1917903B - 止吐剂和脑啡肽酶抑制剂的组合 - Google Patents

止吐剂和脑啡肽酶抑制剂的组合 Download PDF

Info

Publication number
CN1917903B
CN1917903B CN2005800046292A CN200580004629A CN1917903B CN 1917903 B CN1917903 B CN 1917903B CN 2005800046292 A CN2005800046292 A CN 2005800046292A CN 200580004629 A CN200580004629 A CN 200580004629A CN 1917903 B CN1917903 B CN 1917903B
Authority
CN
China
Prior art keywords
pharmaceutical composition
diarrhea
combination
composition according
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800046292A
Other languages
English (en)
Chinese (zh)
Other versions
CN1917903A (zh
Inventor
J-C·施瓦特兹
J-M·勒康特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Bioprojet SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1917903(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet SC filed Critical Bioprojet SC
Publication of CN1917903A publication Critical patent/CN1917903A/zh
Application granted granted Critical
Publication of CN1917903B publication Critical patent/CN1917903B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2005800046292A 2004-02-12 2005-02-14 止吐剂和脑啡肽酶抑制剂的组合 Expired - Fee Related CN1917903B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290384.9 2004-02-12
EP04290384A EP1563848A1 (en) 2004-02-12 2004-02-12 New combinations of an anti-emetic agent and an enkephalinase inhibitor
PCT/IB2005/000351 WO2005079850A1 (en) 2004-02-12 2005-02-14 New combinations of an anti emetic agent and an enkephalinase inhibitor

Publications (2)

Publication Number Publication Date
CN1917903A CN1917903A (zh) 2007-02-21
CN1917903B true CN1917903B (zh) 2010-07-21

Family

ID=34684783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800046292A Expired - Fee Related CN1917903B (zh) 2004-02-12 2005-02-14 止吐剂和脑啡肽酶抑制剂的组合

Country Status (28)

Country Link
US (1) US8222294B2 (enExample)
EP (2) EP1563848A1 (enExample)
JP (1) JP4987487B2 (enExample)
KR (1) KR101152308B1 (enExample)
CN (1) CN1917903B (enExample)
AT (1) ATE468138T1 (enExample)
AU (1) AU2005215262B2 (enExample)
BR (1) BRPI0506631B8 (enExample)
CA (1) CA2553827C (enExample)
CY (1) CY1110202T1 (enExample)
DE (1) DE602005021317D1 (enExample)
DK (1) DK1718337T3 (enExample)
EA (1) EA010625B1 (enExample)
EC (1) ECSP066758A (enExample)
ES (1) ES2344909T3 (enExample)
HR (1) HRP20100363T1 (enExample)
MA (1) MA28354A1 (enExample)
ME (1) ME01175B (enExample)
NO (1) NO337320B1 (enExample)
NZ (1) NZ548635A (enExample)
PL (1) PL1718337T3 (enExample)
PT (1) PT1718337E (enExample)
RS (1) RS51329B (enExample)
SI (1) SI1718337T1 (enExample)
TN (1) TNSN06246A1 (enExample)
UA (1) UA88156C2 (enExample)
WO (1) WO2005079850A1 (enExample)
ZA (1) ZA200605872B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
EP2462922A1 (en) * 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
EP2866789B1 (en) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) * 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
PT2866802T (pt) * 2012-06-28 2016-09-05 Johnson & Johnson Consumer Inc Composições líquidas racecadotril
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
J.M. Lecomte.An overview of clinical studies with racecadotril in adults.International journal of antimicrobial agents14 1.2000,14(1),81-87.
J.M. Lecomte.An overview of clinical studies with racecadotril in adults.International journal of antimicrobial agents14 1.2000,14(1),81-87. *
L.X.Cubeddu et al.Antiemetic activity of ondansetron in acute gastroenteritis.Aliment pharmacol & ther11 1.1997,11(1),185-191.
L.X.Cubeddu et al.Antiemetic activity of ondansetron in acute gastroenteritis.Aliment pharmacol & ther11 1.1997,11(1),185-191. *
M.J.G. Farthing.Introduction Enkephalinase inhibition: a rational approachtoantisecretory therapy for acute diarrhoea.Aliment Pharmacol &Ther13 suppl 6.1999,13(suppl 6),1-2.
M.J.G. Farthing.Introduction Enkephalinase inhibition: a rational approachtoantisecretory therapy for acute diarrhoea.Aliment Pharmacol &Ther13 suppl 6.1999,13(suppl 6),1-2. *
M.P.Primi et al.Racecadotril demonstrates intestial antisecretory activitiy invivo.Aliment pharmacol & ther13 suppl 6.1999,13(suppl 6),3-7.
M.P.Primi et al.Racecadotril demonstrates intestial antisecretory activitiy invivo.Aliment pharmacol & ther13 suppl 6.1999,13(suppl 6),3-7. *

Also Published As

Publication number Publication date
ATE468138T1 (de) 2010-06-15
CY1110202T1 (el) 2015-01-14
DK1718337T3 (da) 2010-07-26
JP4987487B2 (ja) 2012-07-25
CA2553827C (en) 2012-08-07
SI1718337T1 (sl) 2010-08-31
AU2005215262B2 (en) 2011-03-03
MA28354A1 (fr) 2006-12-01
US8222294B2 (en) 2012-07-17
ECSP066758A (es) 2006-11-24
KR20060132691A (ko) 2006-12-21
BRPI0506631B8 (pt) 2021-05-25
KR101152308B1 (ko) 2012-06-11
CA2553827A1 (en) 2005-09-01
NO20063973L (no) 2006-09-05
EP1718337B1 (en) 2010-05-19
US20070275993A1 (en) 2007-11-29
AU2005215262A1 (en) 2005-09-01
ZA200605872B (en) 2008-01-08
BRPI0506631A (pt) 2007-05-08
EP1718337A1 (en) 2006-11-08
JP2007522202A (ja) 2007-08-09
NO337320B1 (no) 2016-03-07
EA010625B1 (ru) 2008-10-30
PT1718337E (pt) 2010-06-16
DE602005021317D1 (de) 2010-07-01
NZ548635A (en) 2009-10-30
CN1917903A (zh) 2007-02-21
WO2005079850A1 (en) 2005-09-01
ES2344909T3 (es) 2010-09-09
BRPI0506631B1 (pt) 2018-12-04
ME01175B (me) 2013-03-20
EP1563848A1 (en) 2005-08-17
EA200601466A1 (ru) 2006-12-29
RS51329B (sr) 2011-02-28
UA88156C2 (ru) 2009-09-25
TNSN06246A1 (fr) 2007-12-03
PL1718337T3 (pl) 2010-09-30
HRP20100363T1 (hr) 2010-07-31

Similar Documents

Publication Publication Date Title
IE58335B1 (en) Pharmaceutical products providing enhanced analgesia
JP4632204B2 (ja) 下痢型過敏性腸症候群治療剤
EP1588707A1 (en) Stable solid medicinal composition for oral administration
RU2738885C1 (ru) Противо-SARS-CoV-2 вирусное средство Антипровир
KR101152308B1 (ko) 항구토제와 엔케팔리나제 억제제의 배합물
CN108992456A (zh) 含有香叶木苷硫酸酯衍生物的药物组合物及其应用
KR100746444B1 (ko) 설사-우세형 과민성 대장 증후군의 치료제
KR20040025913A (ko) 호흡기 질환의 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체
KR20130066874A (ko) 과민성 장 증후군의 예방 또는 치료에 유용한 화합물 및 이를 포함하는 조성물
CZ243898A3 (cs) Vodná formulace bambuterolu a její použití
US7842702B2 (en) Treatment for irritable bowel syndrome
JP6616968B2 (ja) 医薬組成物
WO2009025571A1 (en) Sublingual or buccal pharmaceutical compositions comprising succinic acid for treating alzheimer's disease
WO2010074607A2 (ru) Действующее вещество и фармацевтическая композиция для лечения алкогольной зависимости, способ получения и применения
JP4490668B2 (ja) 下痢治療薬
CN101732320B (zh) 一种新的镇咳药用组合物
US20070244102A1 (en) Combination of Dermaciclane and Opoids as Analgesics
Griffin et al. Niclosamide
WO2005072730A1 (ja) 下痢型過敏性腸症候群治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100721

Termination date: 20210214

CF01 Termination of patent right due to non-payment of annual fee